尖峰集团: 尖峰集团关于子公司获得化学原料药上市申请批准通知书的公告

Group 1 - The core announcement is that Zhejiang Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received the approval notice for the listing application of the chemical raw material drug, Empagliflozin, from the National Medical Products Administration [1][2] - Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which aids in blood sugar control for adult patients with type II diabetes by blocking glucose reabsorption in the kidneys [2] - The total investment in the research and development of the Empagliflozin raw material project is approximately RMB 8.8769 million [2] Group 2 - The approval indicates that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market, which will help expand the subsidiary's business scope [3] - The approval notice is valid until July 24, 2030, and the production facility is located in Jinhua City, Zhejiang Province [2]